In 165 patients with unresectable HCC receiving chemoIO with αPD‐L1, baseline serum IL‐6 concentrations were significantly lower in patients achieving complete response (CR), partial response (PR), or stable disease (SD) >6 months (5.1 pg/mL) compared with those with progressive disease (PD) (11.6 pg/mL).29 The gene discussed is IL6; the disease is hepatocellular carcinoma.